Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response

被引：12

作者：

Fukumoto, Kota ^{[1
]}

Fujisawa, Manabu ^{[1
]}

Suehara, Yasuto ^{[1
]}

Narita, Ken-Taro ^{[1
]}

Usui, Yoshiaki ^{[1
]}

Takeuchi, Masami ^{[1
]}

Matsue, Kosei ^{[1
]}

机构：

[1] Kameda Med Ctr, Dept Internal Med, Div Hematol Oncol, Chiba, Japan

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 08期

关键词：

Complete response; immunophenotypic response; minimal residual disease; multiple myeloma; multicolor flow cytometry; stringent CR; MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; FREE LIGHT-CHAIN; MULTIPARAMETER FLOW-CYTOMETRY; STRINGENT COMPLETE RESPONSE; IMMUNOFIXATION; LENALIDOMIDE; DEXAMETHASONE; COMBINATION; REMISSION;

D O I：

10.3109/10428194.2015.1121262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To investigate the impact of immunophenotypic complete response [iCR, 10(-4) multiple myeloma (MM) cells defined by multicolor flow cytometry (MFC)] on survival in patients with MM, we retrospectively analyzed 78 patients that obtained conventional CR at our hospital. Survivals were landmarked at achievement of CR. The rate of stringent CR (sCR) among patients with CR was 88%, and iCR for CR and sCR patients were 44% and 49%, respectively. Achievement of iCR was associated with significantly longer disease-free survival (DFS) not only in CR patients (p=0.009) but also in sCR patients (p=0.002), while sCR attainment per se did not have statistically significant impact on DFS (p=0.06) or overall survival (OS) (p=0.587). Univariate and multivariate analyses indicated that attainment of iCR was independently associated with longer 2-year DFS in addition to creatinine (2.0mg/dL) and maintenance therapy. This study highlights the importance of pursuing iCR even in patients with sCR.

引用

页码：1786 / 1792

页数：7

共 50 条

[31] Immunophenotypic Response After Allografting In Multiple Myeloma
Giaccone, Luisa
Brunello, Lucia
Passera, Roberto
Festuccia, Moreno
Gilestro, Milena
Maffini, Enrico
Ferrando, Federica
Boccadoro, Mario
Omede, Paola
Bruno, Benedetto
BLOOD, 2013, 122 (21)
[32] IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA
Giaccone, L.
Brunello, L.
Passera, R.
Festuccia, M.
Gilestro, M.
Maffini, E.
Ferrando, F.
Testa, F.
Boccadoro, M.
Omede, P.
Bruno, B.
HAEMATOLOGICA, 2013, 98 : 373 - 373
[33] Attainment of a Stringent Complete Response in Multiple Myeloma with Thalidomide Monotherapy
Aritaka, Nanae
Ichikawa, Kunimoto
Nakamura, Hiroko
Yasuda, Hajime
Ogura, Kanako
Matsumoto, Toshiharu
Komatsu, Norio
Hirano, Takao
INTERNAL MEDICINE, 2012, 51 (19) : 2781 - 2783
[34] Beneficial effect of complete response and type of therapy in multiple myeloma
Pandey, Shivlal
Rajkumar, S. Vincent
Dispenzieri, Angela
Lacy, Martha
Gertz, Morie
Buadi, Francis
Dingli, David
Hayman, Suzanne R.
Russell, Stephen J.
Lust, John Anthony
Zeldenrust, Steven R.
Kapoor, Prashant
McCurdy, Arleigh Robertson
Kyle, Robert A.
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[35] The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Terragna, Carolina
Remondini, Daniel
Martello, Marina
Zamagni, Elena
Pantani, Lucia
Patriarca, Francesca
Pezzi, Annalisa
Levi, Giuseppe
Offidani, Massimo
Proserpio, Ilaria
De Sabbata, Giovanni
Tacchetti, Paola
Cangialosi, Clotilde
Ciambelli, Fabrizio
Vigano, Clara Virginia
Dico, Flores Angela
Santacroce, Barbara
Borsi, Enrica
Brioli, Annamaria
Marzocchi, Giulia
Castellani, Gastone
Martinelli, Giovanni
Palumbo, Antonio
Cavo, Michele
ONCOTARGET, 2016, 7 (09) : 9666 - 9679
[36] Impact of the immunophenotypical and molecular response evaluated by flow cytometry and fluorescent pcr in the follow up of multiple myeloma patients achieving conventional complete response after autologous stem cell transplantation
Martinez-Lopez, J.
Montejano, L.
Martinez-Sanchez, P.
Sarasquete, M. E.
Garcia-Sanz, R.
Montalban, M. A.
Rapado, I.
Garcia-Larana, J.
Martinez, R.
Besalduch, J.
Hernandez, B.
Sanchez-Godoy, P.
Sureda, A.
Blade, J.
de la Rubia, J.
Ayala, R.
Miguel, J. San
Lahuerta, J. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 205 - 206
[37] Prognostic Impact of Complete Response after First Line Therapy on Outcomes Following Initial Relapse in Newly Diagnosed Multiple Myeloma
Tandon, Nidhi
Sidana, Surbhi
Rajkumar, S. Vincent
Gonsalves, Wilson I.
Kapoor, Prashant
Dispenzieri, Angela
Gertz, Morie A.
Warsame, Rahma
Kourelis, Taxiarchis
Lacy, Martha Q.
Dingli, David
Fonder, Amie
Hayman, Suzanne R.
Hobbs, Miriam
Hwa, Yi L.
Buadi, Francis K.
Kyle, Robert A.
Leung, Nelson
Go, Ronald S.
Lust, John A.
Russell, Stephen J.
Kumar, Shaji K.
BLOOD, 2017, 130
[38] The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
Chee, Cheng E.
Kumar, Shaji
Larson, Dirk R.
Kyle, Robert A.
Dispenzieri, Angela
Gertz, Morie A.
Colby, Colin L.
Rajkumar, S. Vincent
BLOOD, 2009, 114 (13) : 2617 - 2618
[39] Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response
D'Auria, Fiorella
La Rocca, Francesco
Simeon, Vittorio
Statuto, Teodora
Pietrantuono, Giuseppe
D'Arena, Giovanni
Villani, Oreste
Mansueto, Giovanna
Traficante, Antonio
Musto, Pellegrino
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (04) : 550 - 552
[40] Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma
Kapoor, Prashant
Gertz, Morie A.
Dispenzieri, Angela
Lacy, Martha Q.
Dingli, David
Hayman, Suzanne R.
Buadi, Francis K.
Russell, Stephen
Lin, Yi
Witzig, Thomas E.
Lust, John A.
Zeldenrust, Steven R.
Greipp, Philip R.
Kyle, Robert A.
Rajkumar, Vincent
Kumar, Shaji K.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →